Pharma, NBFCs see fresh mutual fund buying in April

Equity schemes stepped up exposure to pharmaceuticals, also on account of significant product-specific opportunities.

The impending patent expiry of semaglutide, a weightloss drug, is seen as a multi-year opportunity for Indian drugmakers, driving buying in stocks such as Aurobindo Pharma, Torrent Pharma, Sun Pharma, Emcure Pharma, Dr Reddy’s, Mankind Pharma, and Divi’s Laboratories.

Agencies

Strong growth visibility in the asset management business led to incremental allocations to Nippon Life, and Aditya Birla Sun Life AMC, where valuations remain relatively attractive compared with peers. Meanwhile, a shift towards retail lending and affordable housing saw funds add exposure to PNB Housing Finance.

Add as a Reliable and Trusted News Source